CN111679002A - Reagent kit for antianxiety and hypnotic drugs in serum by ultra-performance liquid chromatography tandem mass spectrometry technology - Google Patents

Abstract

The invention relates to a kit for detecting anxiolytic and hypnotic drugs in serum by an ultra-high performance liquid chromatography tandem mass spectrometry technology, which can detect 11 anxiolytic and hypnotic drugs at one time, simultaneously monitor a target drug and a metabolite, has the advantages of simple pretreatment process, low cost, high sensitivity and strong specificity, completes the separation and detection of the anxiolytic and hypnotic drugs within 5 minutes, basically meets the requirements on accuracy and precision, can be used for quantitative analysis of the anxiolytic and hypnotic drugs in clinic, and provides a simple and rapid detection method for monitoring the treatment concentration of the anxiolytic and hypnotic drugs in serum in clinic.

Description

Reagent kit for antianxiety and hypnotic drugs in serum by ultra-performance liquid chromatography tandem mass spectrometry technology

Technical Field

The invention belongs to the technical field of blood detection, and particularly relates to a kit for detecting anxiolytic and hypnotic drugs in serum by using an ultra-high performance liquid chromatography tandem mass spectrometry technology, wherein the specific drugs are as follows: nitrazepam (Nitrazepam, NZP), Oxazepam (Oxazepam, OXP), Estazolam (Estazolam, ESL), Temazepam (TMP), Alprazolam (APL), Bromazepam (Bromazepam, BZP), Lorazepam (Lorazepam, LZP), Midazolam (Midazolam, MDZ), Zopiclone (Zopiclone, ZPC), diazepam (Diazapam, DZP) and Zolpidem (Zolpidem, ZPM).

Background

Anxiety and insomnia is a common disease, and is generally influenced by three aspects of biology, psychology and society. Benzodiazepine belongs to a psychotropic drug, and has effects of tranquilizing, hypnotizing, antianxiety, anticonvulsant, and relaxing muscle. Benzodiazepine drugs are pharmaceutically-related agonists of benzodiazepine receptors, which exert an inhibitory effect on the Central Nervous System (CNS) and are suitable for the treatment of sleep disorders, anxiety, increased muscle tone or epilepsy.

Examples of benzodiazepines include diazepam (dzpam, DZP), Nitrazepam (Nitrazepam, NZP), Lorazepam (Lorazepam, LZP), Oxazepam (oxx, OXP), Alprazolam (APL ), Temazepam (Temazepam, TMP), and Bromazepam (Bromazepam, BZP).

Diazepam (7-chloro-1-methyl-5-phenyl-3H-1, 4-benzodiazepine-2 [ 1H)]-ketones) are useful in the treatment of aniline diseases, being long-acting benzodiazepines. Oxazepam and temazepam (3-hydroxydiazepam) are 1, 4-benzodiazepine derivatives and are also the main active metabolites of diazepam, and are mainly used as anxiolytic and hypnotic drugs. Lorazepam is also a 1, 4-benzodiazepine derivative, used clinically to treat anxiety associated with or not associated with depressive symptoms, as a preoperative drug, and also as an anticonvulsant for newborns. Nitrazepam has the effect of anti-epileptic hypnosis, the hypnosis effect is stronger than that of diazepam, and lorazepam and oxazepam basically have the same effect as that of diazepam. The alprazolam is one of the most common benzodiazepine medicines in China, is a safe anxiolytic, and has the advantages of quick absorption and high bioavailability. The estazolam is benzodiazepine diazepam hypnotic drug with rapid absorption and medium half-life period

The extracted medicine of the quasi-drugs is generally used as a short-term insomnia prescription. Midazolam has typical benzodiazepines

Has similar pharmacological activity, and has hypnotic, tranquilizing, anticonvulsive, muscle relaxing, amnesia and axilysis effects.In clinical practice, generalized seizures, refractory status epilepticus and muscle spasms are treated by intravenous and intramuscular injection. Midazolam has also been used for conscious sedation and induction of general anesthesia.

Zolpidem (ambrox), in addition to the benzodiazepines, is a prescribed drug for the short-term treatment of insomnia (difficulty in falling or maintaining sleep) and some brain diseases. The zolpidem is a short-acting non-benzodiazepine hypnotic, has hypnotic effect similar to that of benzodiazepine drugs, is different from classical benzodiazepine molecules in molecules, belongs to imidazopyridine, has no effectiveness proved by zolpidem in maintaining sleep, and is effective in shortening sleep time and prolonging sleep time. Zopiclone is a pyrrolidone type sedative hypnotic and can be used for treating insomnia, particularly patients with temporary sleep difficulty and early awakening.

However, these anxiolytic and hypnotic drugs have similar adverse or toxic effects, mainly manifested by dizziness or prolonged sleep time, and reduced attention-focusing ability. Co-administration with other substances inhibiting the central nervous system, in particular alcohol, may lead to severe and even life-threatening respiratory depression. In addition to this, these substances have a high potential to develop tolerance and dependence, which may lead to physical and psychological withdrawal symptoms, leading to misuse and abuse.

Therefore, for toxicology screening, identification and quantification in Clinical Toxicology (CT), appropriate analytical procedures are required. The detection of anxiolytic and hypnotic drugs in serum or serum has important clinical implications for compliance, monitoring and identification of abuse. Determination of serum or serum concentrations helps to optimize chronic dosing, verify compliance, and determine changes in pharmacokinetics.

To date, no general screening procedure has been published for benzodiazepines, zolpidem, and zopiclone in serum, unlike the quantification of this group of single agents or combinations of some of them (some also including metabolites). A large number of assays have been published for serum analysis of different drugs. However, all of these processes involve mixtures of only a single or a few benzodiazepines.

At present, a plurality of patents aiming at the detection of the in vivo concentration of anxiolytic and hypnotic drugs are provided, for example, Chinese patent application (publication number: CN 109085265A) discloses a kit for detecting anxiolytic/hypnotic drugs in serum and plasma by a liquid chromatography tandem mass spectrometry method and application thereof, 8 substances are detected at the same time, the sample size needs 100 muL, the pretreatment needs more than 35 minutes, Chinese patent application (publication number: CN 107991421A) discloses a liquid chromatography analysis method for detecting the diazepam content in blood, the sensitivity of the diazepam is low, the quantification limit is 0.625 mug/mL, the sample size needs 100 muL, the pretreatment is complicated, extraction and nitrogen-blowing concentration are needed. In addition, the detection of one or more of the drugs in the patent has relatively low efficiency, and has the defects of long analysis time of a single sample, low sensitivity, unsuitable linear range, complex sample pretreatment, matrix effect interference and the like.

Disclosure of Invention

The invention aims to provide a kit for detecting anxiolytic and hypnotic drugs in serum by using an ultra-high performance liquid chromatography tandem mass spectrometry technology on the basis of the prior art.

The invention also aims to provide the application of the kit in detecting the anxiolytic and hypnotic drugs in the serum by using the ultra performance liquid chromatography tandem mass spectrometry technology.

The technical scheme of the invention is as follows:

a kit for detecting anxiolytic and hypnotic drugs in serum by ultra-high performance liquid chromatography tandem mass spectrometry,

the anxiolytic and hypnotic drugs are respectively: nitrazepam, oxazepam, estazolam, temazepam, alprazolam, bromoazepam, lorazepam, midazolam, zopiclone, diazepam, and zolpidem;

the kit comprises the following reagents:

(1) eluent:

eluent A: 0.01 to 0.1 percent of acetic acid-0.05 to 0.5mM of ammonium acetate aqueous solution; eluent B: acetonitrile;

(2) calibration solution:

preparing a mixed standard stock solution containing nitrazepam 20000ng/mL, oxazepam 50000ng/mL, estazolam 20000ng/mL, temazepam 40000ng/mL, alprazolam 5000ng/mL, bromazepam 20000ng/mL, lorazepam 10000ng/mL, midazolam 5000ng/mL, zopiclone 20000ng/mL, diazepam 100000ng/mL and zolpidem 10000ng/mL into a calibrator solution with seven concentration points by using a blank serum matrix, wherein the seven concentration points of the calibrator solution are as follows:

the concentrations of alprazolam and midazolam are the same, and seven concentration points are as follows: 0.5ng/mL, 1.25ng/mL, 2.5ng/mL, 12.5ng/mL, 25ng/mL, 125ng/mL, 250 ng/mL;

the lorazepam and zolpidem have the same concentration, and seven concentration points are as follows in sequence: 1ng/mL, 2.5ng/mL, 5ng/mL, 25ng/mL, 50ng/mL, 250ng/mL, 500 ng/mL;

the concentrations of nitrazepam, estazolam, bromoazepam and zopiclone are the same, and seven concentration points are as follows in sequence: 2ng/mL, 5ng/mL, 10ng/mL, 50ng/mL, 100ng/mL, 500ng/mL, 1000 ng/mL;

seven concentration points of temazepam are in order: 4ng/mL, 10ng/mL, 20ng/mL, 100ng/mL, 200ng/mL, 1000ng/mL, 2000 ng/mL;

seven concentration points of oxazepam are as follows in sequence: 5ng/mL, 12.5ng/mL, 25ng/mL, 125ng/mL, 250ng/mL, 1250ng/mL, 2500 ng/mL;

seven concentration points of diazepam are in order: 10/mL, 25ng/mL, 50ng/mL, 250ng/mL, 500ng/mL, 2500ng/mL, 5000 ng/mL;

(3) mixing internal standard solutions:

a methanol solution comprising nitrazepam-d 50.5 μ g/mL, oxazepam-13C 61 μ g/mL, estazolam-d 50.5 μ g/mL, temazepam-d 51 μ g/mL, alprazolam-d 50.5 μ g/mL, bromoazepam-d 40.5 μ g/mL, lorazepam-d 40.2 μ g/mL, midazolam-d 70.1 μ g/mL, zopiclone-d 80.5 μ g/mL, diazepam-d 52 μ g/mL and zolpidem-d 82 μ g/mL;

(4) protein precipitant:

a mixed solution of methanol and isopropanol;

(5) quality control product:

blank serum matrix containing anxiolytic and hypnotic drugs is divided into low, medium and high concentrations, which are QC (L), QC (M) and QC (H), wherein,

QC (L) is the mixed standard stock solution diluted to 5000 times with blank serum matrix;

QC (M) is the above mixed standard stock solution diluted 500 times with blank serum matrix;

qc (h) was a 50-fold dilution of the above mixed standard stock solution in blank serum matrix.

In a preferred embodiment, the eluent A is 0.01% -0.05% acetic acid-0.05-0.1 mM ammonium acetate aqueous solution, preferably 0.05% acetic acid-0.1 mM ammonium acetate aqueous solution.

In one scheme, the volume ratio of methanol to isopropanol in the protein precipitator is 1: 1-5; preferably, the volume ratio of methanol to isopropanol in the protein precipitant is 1: 4.

In one embodiment, the serum blank matrix is a serum blank without anxiolytic and hypnotic agents of interest.

The mixed standard stock solutions mentioned in the present invention were prepared as follows:

the anti-anxiety and hypnotic drugs are prepared into standard mother solutions with the following concentrations: 1mg/mL of nitrazepam, 1mg/mL of oxazepam, 1mg/mL of estazolam, 1mg/mL of temazepam, 0.1mg/mL of alprazolam, 1mg/mL of bromazepam, 1mg/mL of lorazepam, 1mg/mL of midazolam, 5mg/mL of zopiclone, 1mg/mL of diazepam and 0.1mg/mL of zolpidem;

respectively transferring mother liquor of each standard product: nitrazepam 20 μ L, oxazepam 50 μ L, estazolam 20 μ L, temazepam 40 μ L, alprazolam 50 μ L, bromazepam 20 μ L, lorazepam 10 μ L, midazolam 5 μ L, zopiclone 4 μ L, diazepam 100 μ L and zolpidem 100 μ L, and then adding into 581 μ L of methanol to obtain 1mL of mixed standard stock solution.

The mixed internal standard solution mentioned in the invention is prepared according to the following method:

preparing the following isotope internal standard mother liquor by using methanol: nitrazepam-d 50.1mg/mL, oxazepam-13C 61 mg/mL, estazolam-d 50.1mg/mL, temazepam-d 51 mg/mL, alprazolam-d 50.01mg/mL, bromoazepam-d 40.1mg/mL, lorazepam-d 40.1mg/mL, midazolam-d 70.1mg/mL, zopiclone-d 80.1mg/mL, diazepam-d 50.1mg/mL, and zolpidem-d 81 mg/mL;

respectively transferring the internal standard mother liquor of each isotope: nitrazepam-d 55 μ L, oxazepam-13C 61 μ L, estazolam-d 55 μ L, temazepam-d 51 μ L, alprazolam-d 550 μ L, bromoazepam-d 45 μ L, lorazepam-d 42 μ L, midazolam-d 71 μ L, zopiclone-d 85 μ L, diazepam-d 520 μ L and zolpidem-d 82 μ L, and then the mixture is added into 903 μ L of methanol to obtain 1mL of mixed internal standard solution.

The serum mentioned in the invention is human or animal serum.

In a preferred embodiment, the kit for detecting the anxiolytic and hypnotic drugs in the serum by the ultra-high performance liquid chromatography tandem mass spectrometry technology comprises the following reagents:

(1) eluent:

eluent A: 0.05% acetic acid-0.1 mM ammonium acetate in water; eluent B: acetonitrile;

(2) calibration solution:

the anti-anxiety and hypnotic drugs are prepared into standard mother solutions with the following concentrations: 1mg/mL of nitrazepam, 1mg/mL of oxazepam, 1mg/mL of estazolam, 1mg/mL of temazepam, 0.1mg/mL of alprazolam, 1mg/mL of bromazepam, 1mg/mL of lorazepam, 1mg/mL of midazolam, 5mg/mL of zopiclone, 1mg/mL of diazepam and 0.1mg/mL of zolpidem;

respectively transferring mother liquor of each standard product: nitrazepam 20 μ L, oxazepam 50 μ L, estazolam 20 μ L, temazepam 40 μ L, alprazolam 50 μ L, bromazepam 20 μ L, lorazepam 10 μ L, midazolam 5 μ L, zopiclone 4 μ L, diazepam 100 μ L and zolpidem 100 μ L, and then added to 581 μ L of methanol to obtain 1mL of mixed standard stock solution, the concentration of which is shown in table 1 below.

Table 1 stock solutions of mixed standards

The mixed standard stock solution is prepared into calibration solution of seven different concentration points by blank serum matrix (blank serum solution without antianxiety and hypnotic target drugs), and the preparation process is as follows:

adding 10 mu L of mixed standard stock solution into 190 mu L of blank serum matrix to serve as a first high-value concentration point; taking the first high-value concentration point, and diluting the first high-value concentration point with an equal volume of blank serum matrix to obtain a second high-value concentration point; diluting the first high-value concentration point with 9 times volume of blank serum substrate to obtain a third high-value concentration point; diluting the second high-value concentration point with 9 times volume of blank serum substrate to obtain a fourth high-value concentration point; diluting the third high-value concentration point with 9 times volume of blank serum substrate to obtain a fifth high-value concentration point; diluting the fourth high-value concentration point with 9 times volume of blank serum matrix to obtain a sixth high-value concentration point; and (4) diluting the fifth high-value concentration point with blank serum substrate with 4 times of volume to obtain a seventh high-value concentration point. Seven concentration points for the standard formulation are shown in table 2.

TABLE 2 Standard koji preparation

(3) Mixing internal standard solutions:

preparing the following isotope internal standard mother liquor by using methanol: nitrazepam-d 50.1mg/mL, oxazepam-13C 61 mg/mL, estazolam-d 50.1mg/mL, temazepam-d 51 mg/mL, alprazolam-d 50.01mg/mL, bromoazepam-d 40.1mg/mL, lorazepam-d 40.1mg/mL, midazolam-d 70.1mg/mL, zopiclone-d 80.1mg/mL, diazepam-d 50.1mg/mL, and zolpidem-d 81 mg/mL;

respectively transferring the internal standard mother liquor of each isotope: nitrazepam-d 55 μ L, oxazepam-13C 61 μ L, estazolam-d 55 μ L, temazepam-d 51 μ L, alprazolam-d 550 μ L, bromoazepam-d 45 μ L, lorazepam-d 42 μ L, midazolam-d 71 μ L, zopiclone-d 85 μ L, diazepam-d 520 μ L and zolpidem-d 82 μ L, and then the mixture is added into 903 μ L of methanol to obtain 1mL of mixed internal standard solution.

(4) Protein precipitant:

the volume ratio of methanol to isopropanol is 1: 4;

(5) quality control product:

the mixed standard stock solution is prepared into QC (L), QC (M) and QC (H) with three different concentrations by using a blank serum solution without the anxiolytic and hypnotic target drugs, wherein the three different concentrations are specifically shown in Table 3.

TABLE 3 corresponding concentration of anxiolytic and hypnotic drug quality control (concentration unit: ng/mL)

Numbering	Components	QC(L)	QC(M)	QC(H)
					1	NZP	4	40	400
2	OXP	10	100	1000
					3	ESL	4	40	400
4	TMP	8	80	800
					5	APL	1	10	100
6	BZP	4	40	400
					7	LZP	2	20	200
8	MDZ	1	10	100
					9	ZPC	4	40	400
10	DZP	20	200	2000
					11	ZPM	2	20	200

QC (L) includes: nitrazepam 4mg/mL, oxazepam 10mg/mL, estazolam 4mg/mL, temazepam 8mg/mL, alprazolam 1mg/mL, bromazepam 4mg/mL, lorazepam 2mg/mL, midazolam 1mg/mL, zopiclone 4mg/mL, diazepam 20mg/mL, and zolpidem 2 mg/mL.

QC (M) comprises: nitrazepam 40mg/mL, oxazepam 100mg/mL, estazolam 40mg/mL, temazepam 80mg/mL, alprazolam 10mg/mL, bromazepam 40mg/mL, lorazepam 20mg/mL, midazolam 10mg/mL, zopiclone 40mg/mL, diazepam 200mg/mL, and zolpidem 20 mg/mL.

QC (H) includes: nitrazepam 400mg/mL, oxazepam 1000mg/mL, estazolam 400mg/mL, temazepam 800mg/mL, alprazolam 100mg/mL, bromazepam 400mg/mL, lorazepam 200mg/mL, midazolam 100mg/mL, zopiclone 400mg/mL, diazepam 2000mg/mL, and zolpidem 200 mg/mL.

When the kit is used for detecting the anxiolytic and hypnotic drugs in the serum, the mixed internal standard solution and the protein precipitator are mixed according to the volume ratio of 1:99 to prepare the protein precipitator containing the internal standard.

The protein precipitator is a mixed solution of methanol and isopropanol, and in a preferable scheme, the volume ratio of the methanol to the isopropanol in the protein precipitator is 1: 1-5; further preferably, the volume ratio of methanol to isopropanol in the protein precipitant is 1: 4.

In a preferred embodiment, the protein precipitant containing the internal standard is prepared as follows:

preparing isotope internal standard mother liquor of the anxiolytic and hypnotic drug by using methanol respectively, adding the isotope internal standard mother liquor into 903 mu L of methanol, uniformly mixing to obtain 1mL of mixed internal standard solution, adding 200 mu L of the mixed internal standard solution into 19.8mL of methanol and acetonitrile mixed solution (the volume ratio of the methanol to the isopropanol is 1:4), and obtaining the protein precipitator containing the internal standard, wherein the concentration is shown in the following table 4.

Table 4 protein precipitant formulations containing internal standards

The application of the kit in detecting the anxiolytic and hypnotic drugs in the serum by using the ultra-performance liquid chromatography tandem mass spectrometry technology is also within the protection scope of the invention.

The specific detection method comprises the following steps:

a method for detecting the concentration of anxiolytic and hypnotic drugs in serum by ultra-high performance liquid chromatography tandem mass spectrometry,

the anxiolytic and hypnotic drugs are respectively: nitrazepam (NZP), Oxazepam (OXP), Estazolam (ESL), Temazepam (TMP), Alprazolam (APL), Bromazepam (BZP), Lorazepam (LZP), Midazolam (MDZ), Zopiclone (ZPC), Diazepam (DZP) and Zolpidem (ZPM).

The isotope internal standard substances corresponding to the anxiolytic and hypnotic drugs are respectively as follows: nitrazepam-d 5(NZP-d5), oxazepam-13C 6(OXP-13C6), estazolam-d 5(ESL-d5), temazepam-d 5(TMP-d5), alprazolam-d 5(APL-d5), bromoazepam-d 4(BZP-d4), lorazepam-d 4(LZP-d4), midazolam-d 7(MDZ-d7), zopiclone-d 8(ZPC-d8), diazepam-d 5(DZP-d5) and zolpidem-d 8(ZPM-d 8).

Detecting the anxiolytic and hypnotic drugs in the preprocessed serum by adopting an ultra-high performance liquid chromatography tandem mass spectrometry technology, firstly separating a target object to be detected from interfering components in a serum matrix by utilizing the ultra-high performance liquid chromatography, then establishing a calibration curve by utilizing a mass spectrum isotope internal standard quantitative method and taking the concentration ratio of a standard substance and an internal standard substance as an X axis and the peak area ratio of the standard substance and the internal standard substance as a Y axis, and calculating the content of the anxiolytic and hypnotic drugs in the serum, wherein the specific chromatographic conditions are as follows:

(1) ultra-high performance liquid chromatography conditions:

mobile phase A: 0.01 to 0.1 percent of acetic acid-0.05 to 0.5mM of ammonium acetate aqueous solution; mobile phase B: acetonitrile;

the type of the chromatographic column: ACQUITY UPLC CSH C18 (2.1X 50mm, 1.7 μm);

gradient elution is carried out by adopting a mobile phase A and a mobile phase B as a mixed mobile phase, wherein the initial ratio of the mobile phase A to the mobile phase B is 80-100: 20-0; the gradient elution procedure was as follows: the volume ratio of the mobile phase A to the mobile phase B is gradually changed from the initial ratio to 35:65 at a constant speed within 0.0-1.0 min; in 1.0-3.0 minutes, the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 35:65 to 2:98 at a constant speed; in 3.0-5.0 minutes, the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 2:98 to the initial ratio at a constant speed; the time taken for each sample was 5.0 minutes.

(2) Mass spectrum conditions:

in an electrospray ionization positive ion detection mode, a mass spectrum scanning mode of multi-reaction monitoring is adopted, and the capillary voltage is 2.5kV (ESI +); the source temperature is 120 ℃; the desolventizing gas temperature is 500 ℃, the desolventizing gas flow rate is 800L/h, and the taper hole gas flow rate is 150L/h; each target and its corresponding isotope internal standard were monitored simultaneously.

In order to improve the chromatographic separation selectivity, it may be considered to adjust the polarity of the mobile phase. According to the invention, acetic acid and ammonium acetate are added into the mobile phase A, so that the ionization efficiency of certain target compounds can be effectively improved, under the coordination of other conditions, compared with the method for detecting the anxiolytic and hypnotic drugs in the serum by adopting an LC-MS/MS method in the prior art, the method has the advantages of higher sensitivity, simple pretreatment process, low cost, high sensitivity and strong specificity, and the separation and detection of the anxiolytic and hypnotic drugs can be completed within 5 minutes. In a preferable embodiment, the mobile phase A is 0.01-0.05% acetic acid-0.05-0.1 mM ammonium acetate aqueous solution without affecting the effect of the invention. In a more preferred embodiment, mobile phase A is 0.05% acetic acid to 0.1mM ammonium acetate in water.

In chromatography, the choice of the chromatographic column is important and the requirements for the chromatographic column: high column efficiency, good selectivity, high analysis speed and the like. The invention adopts 0.01-0.1% acetic acid-0.05-0.5 mM ammonium acetate water solution and acetonitrile as mobile phases, and the types of chromatographic columns are as follows: the detection kit has the advantages that the detection of samples is not interfered by endogenous substances under the coordination of other conditions, the detection kit is high in sensitivity, strong in specificity, low in cost and simple in pretreatment process, the separation and detection can be completed within 5.0 minutes, and the precision and the accuracy meet the requirements, wherein the detection kit is ACQUITY UPLC CSH C18(2.1 multiplied by 50mm, 1.7 mu m).

When the internal standard method is adopted, the selection of the internal standard substance is very important work. The ideal internal standard should be capable of being added to the sample in an accurate, known amount, and have substantially the same or as consistent as possible physicochemical properties, chromatographic behavior, and response characteristics as the sample being analyzed; under chromatographic conditions, the internal standard must be sufficiently separated from the components of the sample. The invention respectively adopts nitrazepam-d 5(NZP-d5), oxazepam-13C 6(OXP-13C6), estazolam-d 5(ESL-d5), temazepam-d 5(TMP-d5), alprazolam-d 5(APL-d5), bromodiazepam-d 4(BZP-d4), lorazepam-d 4(LZP-d4), midazolam-d 7(MDZ-d7), zopiclone-d 8(ZPC-d8), diazepam-d 5(DZP-d5) and zolpidem-d 8(ZPM-d8) as internal standards, the internal standards and the to-be-tested substances have the same retention time, chemical properties and deuterium effects, and the accuracy of the anxiolytic and hypnotic drugs in serum determination is better.

In a preferable scheme, the initial ratio of the mobile phase A to the mobile phase B is 85-95: 15-5. Further preferably, the initial ratio of mobile phase a to mobile phase B is 90: 10.

In one embodiment, the flow rate is 0.2-0.5 mL/min, preferably 0.3 mL/min.

Further, the column temperature is 35-45 ℃, preferably 45 ℃.

Furthermore, the injection volume is 0.2-5 μ L, preferably 1 μ L.

In a preferred scheme, when the ultra-high performance liquid chromatography tandem mass spectrometry technology is adopted to detect the anxiolytic and hypnotic drugs in the serum, the specific chromatographic conditions are as follows:

(1) high performance liquid chromatography conditions:

mobile phase A: 0.05% acetic acid-0.1 mM ammonium acetate in water;

mobile phase B: acetonitrile;

the type of the chromatographic column: ACQUITY UPLC CSH C18 (2.1X 50mm, 1.7 μm);

the initial ratio of mobile phase a to mobile phase B was 90: 10; adopting a gradient elution mode, wherein the gradient elution process comprises the following steps: the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 99:10 to 35:65 at a constant speed within 0.0-1.0 min; in 1.0-3.0 minutes, the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 35:65 to 2:98 at a constant speed; the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 2:98 to 90:10 at a constant speed within 3.0-5.0 minutes; the time taken for each sample was 5.0 minutes. The gradient elution pattern is detailed in table 5; the flow rate is 0.3mL/min, the column temperature is 45 ℃, and the sample injection volume is 1 mu L;

TABLE 5 mobile phase gradient elution parameters

Time (min)	Flow rate (mL/min)	％A	％B
				0.0	0.3	90	10
1.0	0.3	35	65
				3.0	0.3	2	98
5.0	0.3	90	10

(2) Mass spectrum conditions:

in an electrospray ionization positive ion detection mode, a mass spectrum scanning mode of multi-reaction monitoring is adopted, and the capillary voltage is 2.5kV (ESI +); the source temperature is 120 ℃; the desolventizing gas temperature is 500 ℃, the desolventizing gas flow rate is 800L/h, the taper hole gas flow rate is 150L/h, and the mass spectrum source parameters are shown in Table 6; simultaneously monitoring each target object and the corresponding isotope internal standard thereof; the mass spectrometric acquisition parameters for each target analyte are shown in table 7.

TABLE 6 Mass Spectrometry Source parameters

TABLE 7 measurement of Mass Spectrometry parameters for anxiolytic and hypnotic drugs

The serum mentioned in the invention is human or animal serum.

The pretreated serum was prepared as follows: adding a protein precipitator containing an internal standard into the serum, and then oscillating and centrifuging to obtain a supernatant; the protein precipitator is a mixed solution of methanol and isopropanol; preferably, the volume ratio of the methanol to the isopropanol in the mixed solution of the methanol and the isopropanol is 1: 1-5. Without affecting the effect of the present invention, for example, the volume ratio of methanol to isopropanol in the mixed solution of methanol and isopropanol is 1: 4.

In a preferred embodiment, the pre-treated serum is prepared as follows: taking 50 mu L of serum into a 1.5mL centrifuge tube, adding 200 mu L of protein precipitator (the volume ratio of methanol to isopropanol is 1:4) containing internal standard into the centrifuge tube, oscillating for 3-5 min, centrifuging for 4-10 min at 12000-15000 r/min and 1-5 ℃, transferring 60 mu L of supernatant in the centrifuge tube into a plastic inner lining tube, and carrying out sample injection.

In a more preferred embodiment, the pre-treated serum is prepared as follows: 50 mu L of serum is taken in a 1.5mL centrifuge tube, 200 mu L of protein precipitator containing internal standard (the volume ratio of methanol to isopropanol is 1:4) is added into the centrifuge tube, the mixture is shaken for 5min, and after the centrifuge tube is centrifuged for 5min at 14000r/min and 4 ℃, 60 mu L of supernatant in the centrifuge tube is transferred into a plastic inner lining tube for sample injection, and the sample injection amount is 1 mu L.

In one embodiment, the protein precipitant containing the internal standard is prepared as follows:

preparing the following isotope internal standard mother liquor by using methanol: nitrazepam-d 5(NZP-d5)0.1mg/mL, oxazepam-13C 6(OXP-13C6)1mg/mL, estazolam-d 5(ESL-d5)0.1mg/mL, temazepam-d 5(TMP-d5)1mg/mL, alprazolam-d 5(APL-d5)0.01mg/mL, bromodiazepam-d 4(BZP-d4)0.1mg/mL, lorazepam-d 4(LZP-d4)0.1mg/mL, midazolam-d 7(MDZ-d7)0.1mg/mL, zopiclone-d 8(ZPC-d8)0.1mg/mL, diazepam-d 8 (DZP-d5) 0.5942 mg/mL, and pirimizam-d 639 mg/mL.

Respectively transferring the internal standard mother liquor of each isotope: nitrazepam-d 5(NZP-d5)5 μ L, oxazepam-13C 6(OXP-13C6)1 μ L, estazolam-d 5(ESL-d5)5 μ L, temazepam-d 5(TMP-d5)1 μ L, alprazolam-d 5(APL-d5)50 μ L, bromazepam-d 4(BZP-d4)5 μ L, lorazepam-d 4(LZP-d4)2 μ L, midazolam-d 7(MDZ-d7)1 μ L, zopiclone-d 8(ZPC-d8)5 μ L, diazepam-d 5(DZP-d5)20 μ L and zolpidem-d 8(ZPM-d8)2 μ L, and then adding methanol 903 mL to obtain an internal standard solution.

And adding 200uL of the mixed internal standard solution into 19.8mL of protein precipitant (the volume ratio of methanol to isopropanol is 1:4) to obtain the internal standard-containing protein precipitant.

In one embodiment, the standard solution is prepared as follows:

the anti-anxiety and hypnotic drugs are prepared into standard mother solutions with the following concentrations: nitrazepam (NZP)1mg/mL, Oxazepam (OXP)1mg/mL, Estazolam (ESL)1mg/mL, Temazepam (TMP)1mg/mL, Alprazolam (APL)0.1mg/mL, Bromoazepam (BZP)1mg/mL, Lorazepam (LZP)1mg/mL, Midazolam (MDZ)1mg/mL, Zopiclone (ZPC)5mg/mL, Diazepam (DZP)1mg/mL, and Zolpidem (ZPM)0.1 mg/mL.

Respectively transferring mother liquor of each standard product: nitrazepam (NZP)20 μ L, Oxazepam (OXP)50 μ L, Estazolam (ESL)20 μ L, Temazepam (TMP)40 μ L, Alprazolam (APL)50 μ L, Bromoazepam (BZP)20 μ L, Lorazepam (LZP)10 μ L, Midazolam (MDZ)5 μ L, Zopiclone (ZPC)4 μ L, Diazepam (DZP)100 μ L and Zolpidem (ZPM)100 μ L, and then added to 581 μ L of methanol to obtain 1mL of mixed standard stock solution.

The invention prepares the stock solution of the mixed standard substance into the solutions of the calibrator with seven different concentration points by using a blank serum substrate (the blank serum without the antianxiety and hypnotic target drugs), and the preparation process is as follows:

adding 10 mu L of mixed standard stock solution into 190 mu L of blank serum matrix to serve as a first high-value concentration point; taking the first high-value concentration point, and diluting the first high-value concentration point with an equal volume of blank serum matrix to obtain a second high-value concentration point; diluting the first high-value concentration point with 9 times volume of blank serum substrate to obtain a third high-value concentration point; diluting the second high-value concentration point with 9 times volume of blank serum substrate to obtain a fourth high-value concentration point; diluting the third high-value concentration point with 9 times volume of blank serum substrate to obtain a fifth high-value concentration point; diluting the fourth high-value concentration point with 9 times volume of blank serum matrix to obtain a sixth high-value concentration point; and (4) diluting the fifth high-value concentration point with blank serum substrate with 4 times of volume to obtain a seventh high-value concentration point.

The seven concentration points of the calibrator solution were:

the concentrations of Alprazolam (APL) and Midazolam (MDZ) are the same, and seven concentration points are as follows: 0.5ng/mL, 1.25ng/mL, 2.5ng/mL, 12.5ng/mL, 25ng/mL, 125ng/mL, 250 ng/mL.

The Lorazepam (LZP) and Zolpidem (ZPM) concentrations were the same, with seven concentration points in order: 1ng/mL, 2.5ng/mL, 5ng/mL, 25ng/mL, 50ng/mL, 250ng/mL, 500 ng/mL.

The concentrations of Nitrazepam (NZP), Estazolam (ESL), Bromodiazam (BZP) and Zopiclone (ZPC) are the same, and seven concentration points are as follows: 2ng/mL, 5ng/mL, 10ng/mL, 50ng/mL, 100ng/mL, 500ng/mL, 1000 ng/mL.

Seven concentration points of Temazepam (TMP) are in order: 4ng/mL, 10ng/mL, 20ng/mL, 100ng/mL, 200ng/mL, 1000ng/mL, 2000 ng/mL.

Seven concentration points of Oxazepam (OXP) are in sequence: 5ng/mL, 12.5ng/mL, 25ng/mL, 125ng/mL, 250ng/mL, 1250ng/mL, 2500 ng/mL.

Seven concentration points of Diazepam (DZP) are in order: 10/mL, 25ng/mL, 50ng/mL, 250ng/mL, 500ng/mL, 2500ng/mL, 5000 ng/mL.

50 mu L of sample at each concentration point is taken and put into a 1.5mL centrifuge tube, 200 mu L of protein precipitant containing internal standard (the volume ratio of methanol to isopropanol is 1:4) is added into the centrifuge tube, the mixture is shaken for 5min, and after centrifugation is carried out for 5min at 14000r/min and 4 ℃, 60 mu L of supernatant in the centrifuge tube is transferred into a plastic lining tube for sample injection, and the sample injection amount is 1 mu L.

The invention also comprises a quality control product prepared by the following method: preparing the mixed standard stock solution into QC (L), QC (M) and QC (H) with three different concentrations by using blank serum without anxiolytic and hypnotic target drugs, wherein,

qc (l) was a 5000-fold dilution of the above mixed standard stock solution in blank serum matrix.

Qc (m) is a 500-fold dilution of the above mixed standard stock solution in blank serum matrix.

Qc (h) was a 50-fold dilution of the above mixed standard stock solution in blank serum matrix.

QC (L) includes: nitrazepam 4mg/mL, oxazepam 10mg/mL, estazolam 4mg/mL, temazepam 8mg/mL, alprazolam 1mg/mL, bromazepam 4mg/mL, lorazepam 2mg/mL, midazolam 1mg/mL, zopiclone 4mg/mL, diazepam 20mg/mL, and zolpidem 2 mg/mL.

QC (M) comprises: nitrazepam 40mg/mL, oxazepam 100mg/mL, estazolam 40mg/mL, temazepam 80mg/mL, alprazolam 10mg/mL, bromazepam 40mg/mL, lorazepam 20mg/mL, midazolam 10mg/mL, zopiclone 40mg/mL, diazepam 200mg/mL, and zolpidem 20 mg/mL.

QC (H) includes: nitrazepam 400mg/mL, oxazepam 1000mg/mL, estazolam 400mg/mL, temazepam 800mg/mL, alprazolam 100mg/mL, bromazepam 400mg/mL, lorazepam 200mg/mL, midazolam 100mg/mL, zopiclone 400mg/mL, diazepam 2000mg/mL, and zolpidem 200 mg/mL.

When the kit is used for detecting the anxiolytic and hypnotic drugs in the serum, the sample size is only 50uL, the pretreatment can be completed within about 10 minutes, the detection can be simultaneously performed on 11 substances, and the flux is higher.

By adopting the technical scheme of the invention, the advantages are as follows:

when the kit provided by the invention is used for detecting the anxiolytic and hypnotic drugs in the serum, 11 anxiolytic and hypnotic drugs can be detected at one time, the target drug and the metabolite are monitored simultaneously, the pretreatment process is simple, the cost is low, the sensitivity is high, the specificity is strong, the separation and detection of the anxiolytic and hypnotic drugs are completed within 5 minutes, the accuracy and the precision basically meet the requirements, the kit can be used for the quantitative analysis of the anxiolytic and hypnotic drugs in clinic, and a simple and rapid detection method is provided for the monitoring of the treatment concentration of the anxiolytic and hypnotic drugs in the serum in clinic.

Drawings

FIG. 1 is a selective ion flow chromatogram of an anxiolytic and hypnotic drug standard;

FIG. 2 is a selective ion flow chromatogram of anxiolytic and hypnotic drugs in a serum sample.

Detailed Description

The invention will be better understood from the following examples. However, those skilled in the art will readily appreciate that the description of the embodiments is only for illustrating the present invention and should not be taken as limiting the invention as detailed in the claims.

Example 1:

first, experimental material and instrument

1. Material

The samples were obtained from serum samples collected from the 11 month clinic in 2019 of the heart disease hospital in Wuhan Asia.

(1) The instrument comprises the following steps: xevo TQ-S triple quadrupole mass spectrometer (Waters Corporation); UPLC I-Class ultra high performance liquid chromatography system (with autosampler, Waters Corporation); SCILOGEX D2012 high speed bench top centrifuge (usa); ultra pure water meter (ELGA LabWater, uk); multi-tube Vortex mixer (Vortex genie2, usa); an adjustable pipettor (Eppendorf 0.5-10 muL, 10-100 muL, 100-1000 muL); glassware, graduated cylinders, and the like. .

(2) Reagent consumables: MS grade methanol (Fisher, usa); MS grade acetonitrile (Fisher, usa); HPLC grade acetonitrile (Honeywell, usa); MS grade acetic acid (Fisher, usa); ammonium acetate grade MS (Fisher, usa); HPLC grade methanol (Honeywell, usa); column ACQUITY UPLC CSH C18 (2.1X 50mm, 1.7 μm).

(3) And (3) standard substance: the standard and its corresponding internal standard are shown in Table 8

TABLE 8 Standard and internal standards

Serial number	Name of Chinese	Manufacturer of the product
			1	Nitrazepam	Sigma
2	Nitrazepam-d 5	Discriminating organisms
			3	Diazepam	Sigma
4	Diazepam-d 5	Sigma
			5	Oxazepam	Sigma
6	oxazepam-13C 6	Discriminating organisms
			7	Estazolam	Sigma
8	Estazolam-d 5	Sigma
			9	Temazepam	Discriminating organisms
10	Temazepam-d 5	Discriminating organisms
			11	Zolpidem	National standard material net
12	Zolpidem-d 8	Sigma
			13	Alprazolam	Middle inspection station
14	Alprazolam-d 5	Sigma
			15	Broxipam	Sigma
16	Broxipam-d 4	Discriminating organisms
			17	Lorazepam	Cerilliant
18	Lorazepam-d 4	Sigma
			19	Midazolam	Cerilliant
20	Midazolam-d 7	Discriminating organisms
			21	Zopiclone	TRC
22	Zopiclone-d 8	Discriminating organisms

(4) Quality control product: blank serum matrix containing anxiolytic and hypnotic substances, classified into low, medium and high concentrations, qc (l), qc (m), qc (h), respectively, are shown in table 3.

Second, liquid condition

(1) Chromatographic conditions are as follows: chromatographic conditions are as follows: mobile phase A: 0.05% acetic acid-0.1 mM ammonium acetate-water solution; mobile phase B: and (3) acetonitrile. The type of the chromatographic column: ACQUITY UPLC CSH C18 (2.1X 50mm, 1.7 μm), using gradient elution, as detailed in Table 5. The flow rate was 0.3mL/min, the column temperature was 45 ℃ and the injection volume was 1. mu.L.

(2) Mass spectrum conditions: in an electrospray ionization positive ion detection mode, a mass spectrum scanning mode of multi-reaction monitoring is adopted, and the capillary voltage is 2.5kV (ESI +); the source temperature is 120 ℃; the desolventizing gas temperature is 500 ℃, the desolventizing gas flow rate is 800L/h, the taper hole gas flow rate is 150L/h, and the mass spectrum source parameters are shown in Table 6; simultaneously monitoring each target object and the corresponding isotope internal standard thereof; the mass spectrometric acquisition parameters for each target analyte are shown in table 7.

Second, the experimental procedure

(1) Preparing a standard substance:

the anti-anxiety and hypnotic drugs are prepared into standard mother solutions with the following concentrations: nitrazepam (NZP)1mg/mL, Oxazepam (OXP)1mg/mL, Estazolam (ESL)1mg/mL, Temazepam (TMP)1mg/mL, Alprazolam (APL)0.1mg/mL, Bromoazepam (BZP)1mg/mL, Lorazepam (LZP)1mg/mL, Midazolam (MDZ)1mg/mL, Zopiclone (ZPC)5mg/mL, Diazepam (DZP)1mg/mL, and Zolpidem (ZPM)0.1 mg/mL;

respectively transferring mother liquor of each standard product: nitrazepam (NZP)20 μ L, Oxazepam (OXP)50 μ L, Estazolam (ESL)20 μ L, Temazepam (TMP)40 μ L, Alprazolam (APL)50 μ L, Bromoazepam (BZP)20 μ L, Lorazepam (LZP)10 μ L, Midazolam (MDZ)5 μ L, Zopiclone (ZPC)4 μ L, Diazepam (DZP)100 μ L and Zolpidem (ZPM)100 μ L, and then added to 581 μ L of methanol to obtain 1mL of mixed standard stock solution. See table 1 for details.

The mixed standard stock solution is prepared into a calibrator solution with seven different concentration points by using a blank serum substrate (blank serum without an anxiolytic and hypnotic target drug), and the seven concentration points of the calibrator solution are as follows in table 2:

the concentrations of Alprazolam (APL) and Midazolam (MDZ) are the same, and seven concentration points are as follows: 0.5ng/mL, 1.25ng/mL, 2.5ng/mL, 12.5ng/mL, 25ng/mL, 125ng/mL, 250 ng/mL.

The Lorazepam (LZP) and Zolpidem (ZPM) concentrations were the same, with seven concentration points in order: 1ng/mL, 2.5ng/mL, 5ng/mL, 25ng/mL, 50ng/mL, 250ng/mL, 500 ng/mL.

The concentrations of Nitrazepam (NZP), Estazolam (ESL), Bromodiazam (BZP) and Zopiclone (ZPC) are the same, and seven concentration points are as follows: 2ng/mL, 5ng/mL, 10ng/mL, 50ng/mL, 100ng/mL, 500ng/mL, 1000 ng/mL.

Seven concentration points of Temazepam (TMP) are in order: 4ng/mL, 10ng/mL, 20ng/mL, 100ng/mL, 200ng/mL, 1000ng/mL, 2000 ng/mL.

Seven concentration points of Oxazepam (OXP) are in sequence: 5ng/mL, 12.5ng/mL, 25ng/mL, 125ng/mL, 250ng/mL, 1250ng/mL, 2500 ng/mL.

Seven concentration points of Diazepam (DZP) are in order: 10/mL, 25ng/mL, 50ng/mL, 250ng/mL, 500ng/mL, 2500ng/mL, 5000 ng/mL.

(2) Preparation of mixed internal standard liquid

Preparing the following isotope internal standard mother liquor by using methanol: nitrazepam-d 5(NZP-d5)0.1mg/mL, oxazepam-13C 6(OXP-13C6)1mg/mL, estazolam-d 5(ESL-d5)0.1mg/mL, temazepam-d 5(TMP-d5)1mg/mL, alprazolam-d 5(APL-d5)0.01mg/mL, bromodiazepam-d 4(BZP-d4)0.1mg/mL, lorazepam-d 4(LZP-d4)0.1mg/mL, midazolam-d 7(MDZ-d7)0.1mg/mL, zopiclone-d 8(ZPC-d8)0.1mg/mL, diazepam-d 8 (DZP-d5) 0.5942 mg/mL, and zolam-d 639 mg/mL;

respectively transferring the internal standard mother liquor of each isotope: nitrazepam-d 5(NZP-d5)5 μ L, oxazepam-13C 6(OXP-13C6)1 μ L, estazolam-d 5(ESL-d5)5 μ L, temazepam-d 5(TMP-d5)1 μ L, alprazolam-d 5(APL-d5)50 μ L, bromazepam-d 4(BZP-d4)5 μ L, lorazepam-d 4(LZP-d4)2 μ L, midazolam-d 7(MDZ-d7)1 μ L, zopiclone-d 8(ZPC-d8)5 μ L, diazepam-d 5(DZP-d5)20 μ L and zolpidem-d 8(ZPM-d8)2 μ L, and then adding methanol 903 mL to obtain an internal standard solution.

(3) Preparing a quality control product:

the mixed standard stock solution is prepared into QC (L), QC (M) and QC (H) with three different concentrations by blank serum without anxiolytic and hypnotic target drugs, and the detail is shown in a table 3.

QC (L) includes: nitrazepam 4mg/mL, oxazepam 10mg/mL, estazolam 4mg/mL, temazepam 8mg/mL, alprazolam 1mg/mL, bromazepam 4mg/mL, lorazepam 2mg/mL, midazolam 1mg/mL, zopiclone 4mg/mL, diazepam 20mg/mL, and zolpidem 2 mg/mL;

QC (M) comprises: nitrazepam 40mg/mL, oxazepam 100mg/mL, estazolam 40mg/mL, temazepam 80mg/mL, alprazolam 10mg/mL, bromazepam 40mg/mL, lorazepam 20mg/mL, midazolam 10mg/mL, zopiclone 40mg/mL, diazepam 200mg/mL and zolpidem 20 mg/mL;

QC (H) includes: nitrazepam 400mg/mL, oxazepam 1000mg/mL, estazolam 400mg/mL, temazepam 800mg/mL, alprazolam 100mg/mL, bromazepam 400mg/mL, lorazepam 200mg/mL, midazolam 100mg/mL, zopiclone 400mg/mL, diazepam 2000mg/mL, and zolpidem 200 mg/mL.

(4) Sample processing

And adding 200 mu L of the mixed internal standard solution into 19.8mL of protein precipitant (the volume ratio of methanol to isopropanol is 1:4) to obtain the protein precipitant containing the internal standard.

1) Pretreatment of a standard product: 50 mu L of sample at each concentration point is taken and put into a 1.5mL centrifuge tube, 200 mu L of protein precipitant containing internal standard (the volume ratio of methanol to isopropanol is 1:4) is added into the centrifuge tube, the mixture is shaken for 5min, and after centrifugation is carried out for 5min at 14000r/min and 4 ℃, 60 mu L of supernatant in the centrifuge tube is transferred into a plastic lining tube for sample injection, and the sample injection amount is 1 mu L.

2) Pretreatment of a serum sample: 50 mu L of serum is taken in a 1.5mL centrifuge tube, 200 mu L of protein precipitator containing internal standard (the volume ratio of methanol to isopropanol is 1:4) is added into the centrifuge tube, the mixture is shaken for 5min, and after the centrifuge tube is centrifuged for 5min at 14000r/min and 4 ℃, 60 mu L of supernatant in the centrifuge tube is transferred into a plastic inner lining tube for sample injection, and the sample injection amount is 1 mu L.

3) Pretreatment of quality control products: the quality control solutions QC (L), QC (M), QC (H) are respectively taken and 50 μ L of each quality control solution QC (L), QC (M), QC (H) are respectively put into a 1.5mL centrifuge tube, and then the quality control solutions QC (L), QC (M), QC (H) are consistent with the pretreatment of the serum sample, and the details are not.

The components of the assay kit are shown in Table 9.

TABLE 9 preparation of kit Components for analysis of concentration of anxiolytic and hypnotic drugs

Fourth, method verification

1. Extracting an ion current chromatogram: the peak shapes of the standard substance of the anxiolytic and hypnotic drug and the serum sample are symmetrical, and have no interference of a hybrid peak, which indicates that good detection can be obtained under the condition, and fig. 1 is a selective ion current chromatogram map of the standard substance of the anxiolytic and hypnotic drug; FIG. 2 is a selective ion flow chromatogram of anxiolytic and hypnotic drugs in a serum sample.

2. Calibration curve: and establishing a calibration curve by adopting an isotope internal standard quantitative method and utilizing TargetLynx software to calculate the concentration of the substance to be detected in the serum by taking the concentration ratio of the standard substance to the internal standard substance as an X axis and the peak area ratio of the standard substance to the internal standard substance as a Y axis. The linear fitting equation of the anxiolytic and hypnotic drugs in the respective concentration ranges has good linearity, the correlation coefficient is more than 0.99, and the quantitative requirements are met, which is shown in table 10.

TABLE 10 linear regression equation and linear correlation coefficient for anxiolytic and hypnotic drugs

3. Accuracy survey: and evaluating the accuracy of the method by adopting a standard recovery rate test. A mixed blank serum sample is prepared, 3 concentrations of mixed standard substances of low, medium and high are respectively added, the treatment and the measurement are repeated for 5 times by the same step, the result shows that the adding standard recovery rate of the anxiolytic and hypnotic drugs is between 88.63 percent and 111.62 percent, the RSD of 5 repeated tests is in the range of 1.34 percent to 7.32 percent, and the statistical result is shown in a table 11.

TABLE 11 results of recovery of anxiolytic and hypnotic drug addition

4. And (3) precision test: taking an interference-free blank serum sample, adding different concentrations of antianxiety and hypnotic drug standard substances to obtain serum samples with low, medium and high concentrations, repeatedly processing 6 batches in one day for three days continuously, quantitatively determining the concentration of the antianxiety and hypnotic drug by an isotope internal standard method, wherein the batch precision is 1.87-8.00%, processing 3 batches in three days, and calculating the batch precision to be 2.64-11.53%, and the result is shown in Table 12.

TABLE 12 results of inter-batch precision measurements (concentration units: ng/mL)

Fifth, discuss

The concentration of the anxiolytic and hypnotic in human serum is measured by an ID-UPLC-MS/MS method. Meanwhile, the method detects the peak time and the ion pair of the target object, has high sensitivity, can greatly eliminate matrix interference by adopting an isotope internal standard method for quantification, is not influenced by the conditions of pretreatment process, sample loading volume and flow and the like, and can achieve accurate quantification.

The result of the accuracy of the method is evaluated by the standard recovery rate test, and shows that the standard recovery rate of the anxiolytic and hypnotic is 88.63% -111.62%, and the RSD of 5 times of repeated tests is 1.34% -7.32%, so that the accuracy is good.

The reproducibility of the method indicates that the intra-batch precision of the anxiolytic and hypnotic drugs is 1.87-8.00% and the inter-batch precision is 2.64-11.53%. The established serum sample pretreatment process is very simple, protein precipitation is completed in one step, and the serum dosage is only 50 mu L.

In a word, the method has the advantages of high sensitivity, strong specificity, accuracy and simpler pretreatment process, can finish the separation and detection of the compound within 5.0 minutes, meets the requirements on accuracy and precision, can be used for quantitative analysis of the concentration of the serum anxiolytic and hypnotic drugs in clinic, and provides a reliable detection method for the treatment and monitoring of the concentration of the anxiolytic and hypnotic drugs in clinic.

The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: modifications of the technical solutions described in the foregoing embodiments are still possible, or some technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.

Claims (10)

1. A kit for detecting anxiolytic and hypnotic drugs in serum by ultra-high performance liquid chromatography tandem mass spectrometry,

the anxiolytic and hypnotic drugs are respectively: nitrazepam, oxazepam, estazolam, temazepam, alprazolam, bromoazepam, lorazepam, midazolam, zopiclone, diazepam, and zolpidem;

the kit comprises the following reagents:

(1) eluent:

eluent A: 0.01 to 0.1 percent of acetic acid-0.05 to 0.5mM of ammonium acetate aqueous solution; eluent B: acetonitrile;

(2) calibration solution:

preparing a mixed standard stock solution containing nitrazepam 20000ng/mL, oxazepam 50000ng/mL, estazolam 20000ng/mL, temazepam 40000ng/mL, alprazolam 5000ng/mL, bromazepam 20000ng/mL, lorazepam 10000ng/mL, midazolam 5000ng/mL, zopiclone 20000ng/mL, diazepam 100000ng/mL and zolpidem 10000ng/mL into a calibrator solution with seven concentration points by using a blank serum matrix, wherein the seven concentration points of the calibrator solution are as follows:

the concentrations of alprazolam and midazolam are the same, and seven concentration points are as follows: 0.5ng/mL, 1.25ng/mL, 2.5ng/mL, 12.5ng/mL, 25ng/mL, 125ng/mL, 250 ng/mL;

the lorazepam and zolpidem have the same concentration, and seven concentration points are as follows in sequence: 1ng/mL, 2.5ng/mL, 5ng/mL, 25ng/mL, 50ng/mL, 250ng/mL, 500 ng/mL;

the concentrations of nitrazepam, estazolam, bromoazepam and zopiclone are the same, and seven concentration points are as follows in sequence: 2ng/mL, 5ng/mL, 10ng/mL, 50ng/mL, 100ng/mL, 500ng/mL, 1000 ng/mL;

seven concentration points of temazepam are in order: 4ng/mL, 10ng/mL, 20ng/mL, 100ng/mL, 200ng/mL, 1000ng/mL, 2000 ng/mL;

seven concentration points of oxazepam are as follows in sequence: 5ng/mL, 12.5ng/mL, 25ng/mL, 125ng/mL, 250ng/mL, 1250ng/mL, 2500 ng/mL;

seven concentration points of diazepam are in order: 10/mL, 25ng/mL, 50ng/mL, 250ng/mL, 500ng/mL, 2500ng/mL, 5000 ng/mL;

(3) mixing internal standard solutions:

a methanol solution comprising nitrazepam-d 50.5 μ g/mL, oxazepam-13C 61 μ g/mL, estazolam-d 50.5 μ g/mL, temazepam-d 51 μ g/mL, alprazolam-d 50.5 μ g/mL, bromoazepam-d 40.5 μ g/mL, lorazepam-d 40.2 μ g/mL, midazolam-d 70.1 μ g/mL, zopiclone-d 80.5 μ g/mL, diazepam-d 52 μ g/mL and zolpidem-d 82 μ g/mL;

(4) protein precipitant:

a mixed solution of methanol and isopropanol;

(5) quality control product:

blank serum matrix containing anxiolytic and hypnotic drugs is divided into low, medium and high concentrations, which are QC (L), QC (M) and QC (H), wherein,

QC (L) is the mixed standard stock solution diluted to 5000 times with blank serum matrix;

QC (M) is the above mixed standard stock solution diluted 500 times with blank serum matrix;

qc (h) was a 50-fold dilution of the above mixed standard stock solution in blank serum matrix.

2. The kit according to claim 1,

the eluent A is 0.01 to 0.05 percent of acetic acid-0.05 to 0.1mM ammonium acetate aqueous solution, and preferably 0.05 percent of acetic acid-0.1 mM ammonium acetate aqueous solution.

3. The kit according to claim 1,

the volume ratio of methanol to isopropanol in the protein precipitator is 1: 1-5; preferably, the volume ratio of methanol to isopropanol in the protein precipitant is 1: 4.

4. The kit according to claim 1,

the blank serum matrix is blank serum without anxiolytic and hypnotic target drugs.

5. The kit according to claim 1, 2, 3 or 4,

the mixed standard stock solution was prepared as follows:

the anti-anxiety and hypnotic drugs are prepared into standard mother solutions with the following concentrations: 1mg/mL of nitrazepam, 1mg/mL of oxazepam, 1mg/mL of estazolam, 1mg/mL of temazepam, 0.1mg/mL of alprazolam, 1mg/mL of bromazepam, 1mg/mL of lorazepam, 1mg/mL of midazolam, 5mg/mL of zopiclone, 1mg/mL of diazepam and 0.1mg/mL of zolpidem;

respectively transferring mother liquor of each standard product: nitrazepam 20 μ L, oxazepam 50 μ L, estazolam 20 μ L, temazepam 40 μ L, alprazolam 50 μ L, bromazepam 20 μ L, lorazepam 10 μ L, midazolam 5 μ L, zopiclone 4 μ L, diazepam 100 μ L and zolpidem 100 μ L, and then adding into 581 μ L of methanol to obtain 1mL of mixed standard stock solution.

6. The kit according to claim 5,

the mixed internal standard solution is prepared according to the following method:

preparing the following isotope internal standard mother liquor by using methanol: nitrazepam-d 50.1mg/mL, oxazepam-13C 61 mg/mL, estazolam-d 50.1mg/mL, temazepam-d 51 mg/mL, alprazolam-d 50.01mg/mL, bromoazepam-d 40.1mg/mL, lorazepam-d 40.1mg/mL, midazolam-d 70.1mg/mL, zopiclone-d 80.1mg/mL, diazepam-d 50.1mg/mL, and zolpidem-d 81 mg/mL;

respectively transferring the internal standard mother liquor of each isotope: nitrazepam-d 55 μ L, oxazepam-13C 61 μ L, estazolam-d 55 μ L, temazepam-d 51 μ L, alprazolam-d 550 μ L, bromoazepam-d 45 μ L, lorazepam-d 42 μ L, midazolam-d 71 μ L, zopiclone-d 85 μ L, diazepam-d 520 μ L and zolpidem-d 82 μ L, and then the mixture is added into 903 μ L of methanol to obtain 1mL of mixed internal standard solution.

7. The kit according to claim 1,

the serum is human or animal blood serum.

8. The kit according to claim 6,

the kit comprises the following reagents:

(1) eluent:

eluent A: 0.05% acetic acid-0.1 mM ammonium acetate in water; eluent B: acetonitrile;

(2) calibration solution:

the anti-anxiety and hypnotic drugs are prepared into standard mother solutions with the following concentrations: 1mg/mL of nitrazepam, 1mg/mL of oxazepam, 1mg/mL of estazolam, 1mg/mL of temazepam, 0.1mg/mL of alprazolam, 1mg/mL of bromazepam, 1mg/mL of lorazepam, 1mg/mL of midazolam, 5mg/mL of zopiclone, 1mg/mL of diazepam and 0.1mg/mL of zolpidem;

respectively transferring mother liquor of each standard product: 20 mu L of nitrazepam, 50 mu L of oxazepam, 20 mu L of estazolam, 40 mu L of temazepam, 50 mu L of alprazolam, 20 mu L of bromazepam, 10 mu L of lorazepam, 5 mu L of midazolam, 4 mu L of zopiclone, 100 mu L of diazepam and 100 mu L of zolpidem, and adding the obtained mixture into 581 mu L of methanol to obtain 1mL of mixed standard stock solution; preparing the mixed standard stock solution into calibration solution with seven different concentration points by blank serum without the anxiolytic and hypnotic target drugs;

(3) mixing internal standard solutions:

preparing the following isotope internal standard mother liquor by using methanol: nitrazepam-d 50.1mg/mL, oxazepam-13C 61 mg/mL, estazolam-d 50.1mg/mL, temazepam-d 51 mg/mL, alprazolam-d 50.01mg/mL, bromoazepam-d 40.1mg/mL, lorazepam-d 40.1mg/mL, midazolam-d 70.1mg/mL, zopiclone-d 80.1mg/mL, diazepam-d 50.1mg/mL, and zolpidem-d 81 mg/mL;

respectively transferring the internal standard mother liquor of each isotope: nitrazepam-d 55 μ L, oxazepam-13C 61 μ L, estazolam-d 55 μ L, temazepam-d 51 μ L, alprazolam-d 550 μ L, bromoazepam-d 45 μ L, lorazepam-d 42 μ L, midazolam-d 71 μ L, zopiclone-d 85 μ L, diazepam-d 520 μ L and zolpidem-d 82 μ L, and then adding into 903 μ L of methanol to obtain 1mL of mixed internal standard solution;

(4) protein precipitant:

the volume ratio of methanol to isopropanol is 1: 4;

(5) quality control product:

preparing the mixed standard stock solution into QC (L), QC (M) and QC (H) with three different concentrations by using blank serum without anxiolytic and hypnotic target drugs, wherein,

QC (L) includes: nitrazepam 4mg/mL, oxazepam 10mg/mL, estazolam 4mg/mL, temazepam 8mg/mL, alprazolam 1mg/mL, bromazepam 4mg/mL, lorazepam 2mg/mL, midazolam 1mg/mL, zopiclone 4mg/mL, diazepam 20mg/mL, and zolpidem 2 mg/mL;

QC (M) comprises: nitrazepam 40mg/mL, oxazepam 100mg/mL, estazolam 40mg/mL, temazepam 80mg/mL, alprazolam 10mg/mL, bromazepam 40mg/mL, lorazepam 20mg/mL, midazolam 10mg/mL, zopiclone 40mg/mL, diazepam 200mg/mL and zolpidem 20 mg/mL;

QC (H) includes: nitrazepam 400mg/mL, oxazepam 1000mg/mL, estazolam 400mg/mL, temazepam 800mg/mL, alprazolam 100mg/mL, bromazepam 400mg/mL, lorazepam 200mg/mL, midazolam 100mg/mL, zopiclone 400mg/mL, diazepam 2000mg/mL, and zolpidem 200 mg/mL.

9. The kit of claim 8, wherein the internal standard-containing protein precipitant is prepared by mixing the mixed internal standard solution and the protein precipitant in a volume ratio of 1:99, and is used for ultra high performance liquid chromatography detection.

10. Use of the kit according to any one of claims 1 to 9 for detecting anxiolytic and hypnotic drugs in serum by ultra performance liquid chromatography tandem mass spectrometry.

Images